Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes
40
about 2.2 years
18–40
1 site in VA
About this study
Researchers are testing whether artificial pancreas technology can improve blood sugar control, reduce blood glucose variability, and potentially benefit cardiovascular health in people with type 1 diabetes. The trial will evaluate if improvements in blood sugar levels lead to a decrease in inflammation and other markers of heart disease risk.
Based on ClinicalTrials.gov records.
What participants do
- 1.Use Sensor augmented pump (SAP) therapy
- 2.Use Tandem t:slim X2 with Control-IQ Technology
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Secondary: Brachial artery flow-mediated dilation (FMD), Carotid Femoral Pulse Wave Velocity (cfPWV), High-sensitivity C-reactive protein (hs-CRP), Insulin sensitivity, Interleukin-6 (IL-6), Myocardial Perfusion (measured by contrast-enhanced ultrasound [CEU])
Endocrinology